{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:58:52Z","timestamp":1792648732729,"version":"4.5.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41585-018-0117-7","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T09:30:32Z","timestamp":1541410232000},"page":"172-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Nonsurgical management of Peyronie\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Peter","family":"Tsambarlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"117_CR1","first-page":"425","volume":"1","author":"FG Peyronie de la","year":"1743","unstructured":"de la Peyronie, F. G. Sur quelques obstacles qui s\u2019opposent a l\u2019ejaculation naturelle de la semence [French]. M\u00e9m. Acad. R. Chir. 1, 425\u2013434 (1743).","journal-title":"M\u00e9m. Acad. R. Chir"},{"key":"117_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","volume":"88","author":"U Schwarzer","year":"2001","unstructured":"Schwarzer, U. et al. The prevalence of Peyronie\u2019s disease: results of a large survey. BJU Int. 88, 727\u2013730 (2001).","journal-title":"BJU Int."},{"key":"117_CR3","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","volume":"171","author":"JP Mulhall","year":"2004","unstructured":"Mulhall, J. P. et al. Subjective and objective analysis of the prevalence of Peyronie\u2019s disease in a population of men presenting for prostate cancer screening. J.\u00a0Urol. 171, 2350\u20132353 (2004).","journal-title":"J. Urol."},{"key":"117_CR4","doi-asserted-by":"publisher","first-page":"282503","DOI":"10.1155\/2011\/282503","volume":"2011","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti, D. B., Nguyen, D., Zografos, L., Ziemiecki, R. & Zhou, X. A. Population-based study of Peyronie\u2019s disease: prevalence and treatment patterns in the United States. Adv. Urol. 2011, 282503 (2011).","journal-title":"Adv. Urol."},{"key":"117_CR5","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph, D. et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J. Sex. Med. 7, 2359\u20132374 (2010).","journal-title":"J. Sex. Med."},{"issue":"Suppl. 5","key":"117_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/sj.ijir.3901082","volume":"15","author":"JP Mulhall","year":"2003","unstructured":"Mulhall, J. P. Expanding the paradigm for plaque development in Peyronie\u2019s disease. Int. J. Impot. Res. 15 (Suppl. 5), 93\u2013102 (2003).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.ijir.3900877","volume":"14","author":"JP Pryor","year":"2002","unstructured":"Pryor, J. P. & Ralph, D. J. Clinical presentations of Peyronie\u2019s disease. Int. J. Impot. Res. 14, 414\u2013417 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.ijir.3900635","volume":"13","author":"A Tefekli","year":"2001","unstructured":"Tefekli, A. et al. Peyronie\u2019s disease in men under age 40: characteristics and outcome. Int. J. Impot. Res. 13, 18\u201323 (2001).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/ijir.2011.18","volume":"23","author":"HM Nugteren","year":"2011","unstructured":"Nugteren, H. M., Nijman, J. M., de Jong, I. J. & van Driel, M. F. The association between Peyronie\u2019s and Dupuytren\u2019s disease. Int. J. Impot. Res. 23, 142\u2013145 (2011).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11552-010-9306-4","volume":"6","author":"DB Dibenedetti","year":"2011","unstructured":"Dibenedetti, D. B., Nguyen, D., Zografos, L., Ziemiecki, R. & Zhou, X. Prevalence, incidence, and treatments of Dupuytren\u2019s disease in the United States: results from a population-based study. Hand 6, 149\u2013158 (2011).","journal-title":"Hand"},{"key":"117_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0022-5347(01)65366-7","volume":"157","author":"L Water Van de","year":"1997","unstructured":"Van de Water, L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for\u00a0Peyronie\u2019s disease. J. Urol. 157, 306\u2013310 (1997).","journal-title":"J. Urol."},{"key":"117_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0022-5347(01)65364-3","volume":"157","author":"RF Diegelmann","year":"1997","unstructured":"Diegelmann, R. F. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J. Urol. 157, 298\u2013302 (1997).","journal-title":"J. Urol."},{"key":"117_CR13","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1046\/j.1464-410X.2003.04224.x","volume":"91","author":"HH Davila","year":"2003","unstructured":"Davila, H. H., Ferrini, M. G., Rajfer, J. & Gonzalez-Cadavid, N. F. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie\u2019s disease. BJU Int. 91, 830\u2013838 (2003).","journal-title":"BJU Int."},{"key":"117_CR14","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0022-5347(01)68236-3","volume":"158","author":"AI El-Sakka","year":"1997","unstructured":"El-Sakka, A. I. et al. An animal model of Peyronie\u2019s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J.\u00a0Urol. 158, 2284\u20132290 (1997).","journal-title":"J. Urol."},{"key":"117_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1083\/jcb.105.3.1039","volume":"105","author":"MB Sporn","year":"1987","unstructured":"Sporn, M. B., Roberts, A. B., Wakefield, L. M. & de Crombrugghe, B. Some recent advances in the chemistry and biology of transforming growth factor-beta. J. Cell Biol. 105, 1039\u20131045 (1987).","journal-title":"J. Cell Biol."},{"key":"117_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.ijir.3900875","volume":"14","author":"RB Moreland","year":"2002","unstructured":"Moreland, R. B. & Nehra, A. Pathophysiology of Peyronie\u2019s disease. Int. J. Impot. Res. 14, 406\u2013410 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1464-410x.1998.00529.x","volume":"81","author":"AI El-Sakka","year":"1998","unstructured":"El-Sakka, A. I. et al. Histological and ultrastructural alterations in an animal model of Peyronie\u2019s disease. Br. J. Urol. 81, 445\u2013452 (1998).","journal-title":"Br. J. Urol."},{"key":"117_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","volume":"14","author":"JP Mulhall","year":"2002","unstructured":"Mulhall, J. P., Anderson, M. S., Lubrano, T. & Shankey, T. V. Peyronie\u2019s disease cell culture models: phenotypic, genotypic and functional analyses. Int. J.\u00a0Impot. Res. 14, 397\u2013405 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.juro.2008.01.093","volume":"179","author":"M Carlo Del","year":"2008","unstructured":"Del Carlo, M., Cole, A. A. & Levine, L. A. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie\u2019s plaque fibroblasts. J. Urol. 179, 2447\u20132455 (2008).","journal-title":"J. Urol."},{"key":"117_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/niox.2001.0421","volume":"6","author":"MG Ferrini","year":"2002","unstructured":"Ferrini, M. G. et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 6, 283\u2013294 (2002).","journal-title":"Nitric Oxide"},{"key":"117_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","volume":"7","author":"D Vernet","year":"2002","unstructured":"Vernet, D. et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie\u2019s fibrotic plaque and in its rat model. Nitric Oxide 7, 262\u2013276 (2002).","journal-title":"Nitric Oxide"},{"key":"117_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jsm.12838","volume":"12","author":"KS Coyne","year":"2015","unstructured":"Coyne, K. S., Currie, B. M., Thompson, C. L. & Smith, T. M. Responsiveness of the Peyronie\u2019s disease questionnaire (PDQ). J. Sex. Med. 12, 1072\u20131079 (2015).","journal-title":"J. Sex. Med."},{"key":"117_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom, W. J. et al. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J. Urol. 190, 627\u2013634 (2013).","journal-title":"J. Urol."},{"key":"117_CR24","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"JP Mulhall","year":"2006","unstructured":"Mulhall, J. P., Schiff, J. & Guhring, P. An analysis of the natural history of Peyronie\u2019s disease. J. Urol. 175, 2115\u20132118; discussion 2118 (2006).","journal-title":"J. Urol."},{"key":"117_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.sxmr.2017.12.006","volume":"6","author":"JY Chen","year":"2018","unstructured":"Chen, J. Y., Hockenberry, M. S. & Lipshultz, L. I. Objective assessments of Peyronie\u2019s disease. Sex. Med. Rev. 6, 438\u2013445 (2018).","journal-title":"Sex. Med. Rev."},{"key":"117_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ijir.2011.36","volume":"23","author":"E Chung","year":"2011","unstructured":"Chung, E., De Young, L. & Brock, G. B. Rat as an animal model for Peyronie\u2019s disease research: a review of current methods and the peer-reviewed literature. Int. J. Impot. Res. 23, 235\u2013241 (2011).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1743-6109.2012.03003.x","volume":"10","author":"LA Levine","year":"2013","unstructured":"Levine, L. A. & Burnett, A. L. Standard operating procedures for Peyronie\u2019s disease. J. Sex. Med. 10, 230\u2013244 (2013).","journal-title":"J. Sex. Med."},{"key":"117_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/sj.ijir.3900880","volume":"14","author":"SC Sikka","year":"2002","unstructured":"Sikka, S. C. & Hellstrom, W. J. Role of oxidative stress and antioxidants in Peyronie\u2019s disease. Int. J. Impot. Res. 14, 353\u2013360 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","volume":"1","author":"G Paulis","year":"2013","unstructured":"Paulis, G. et al. Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases. Andrology 1, 120\u2013128 (2013).","journal-title":"Andrology"},{"key":"117_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1442-2042.2006.01270.x","volume":"13","author":"K Hashimoto","year":"2006","unstructured":"Hashimoto, K. et al. Outcome analysis for conservative management of Peyronie\u2019s disease. Int. J. Urol. 13, 244\u2013247 (2006).","journal-title":"Int. J. Urol."},{"key":"117_CR31","first-page":"41","volume":"9","author":"JP Pryor","year":"1983","unstructured":"Pryor, J. P., & Farrell, C. F. Controlled clinic trial of vitamin E in Peyronie\u2019s disease. Prog. Reprod. Biol. 9, 41\u201345 (1983).","journal-title":"Reprod. Biol."},{"key":"117_CR32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"MR Safarinejad","year":"2007","unstructured":"Safarinejad, M. R., Hosseini, S. Y. & Kolahi, A. A. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study. J. Urol. 178, 1398\u20131403; discussion 1403 (2007).","journal-title":"J. Urol."},{"key":"117_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2005.02.053","volume":"107","author":"LA Calo","year":"2006","unstructured":"Calo, L. A. et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int. J. Cardiol. 107, 54\u201360 (2006).","journal-title":"Int. J. Cardiol."},{"key":"117_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","volume":"88","author":"G Biagiotti","year":"2001","unstructured":"Biagiotti, G. & Cavallini, G. Acetyl-L-carnitine versus tamoxifen in the oral therapy of Peyronie\u2019s disease: a\u00a0preliminary report. BJU Int. 88, 63\u201367 (2001).","journal-title":"BJU Int"},{"key":"117_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","volume":"9","author":"EG Valente","year":"2003","unstructured":"Valente, E. G. et al. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie\u2019s fibrotic plaque and related fibroblast cultures. Nitric\u00a0Oxide 9, 229\u2013244 (2003).","journal-title":"Nitric Oxide"},{"key":"117_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/aiua.2013.1.36","volume":"85","author":"F Ciociola","year":"2013","unstructured":"Ciociola, F. & Colpi, G. M. Peyronie\u2019s disease: a \u201ctriple oxygenant therapy\u201d. Arch. Ital. Urol. Androl. 85, 36\u201340 (2013).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"117_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","volume":"9","author":"MR Abern","year":"2012","unstructured":"Abern, M. R., Larsen, S. & Levine, L. A. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease. J. Sex. Med. 9, 288\u2013295 (2012).","journal-title":"J. Sex. Med."},{"key":"117_CR38","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/j.1743-6109.2010.01790.x","volume":"7","author":"AW Shindel","year":"2010","unstructured":"Shindel, A. W. et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J. Sex. Med. 7, 2077\u20132085 (2010).","journal-title":"J. Sex. Med."},{"key":"117_CR39","first-page":"30","volume":"76","author":"L Schandene","year":"1992","unstructured":"Schandene, L. et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 76, 30\u201334 (1992).","journal-title":"Immunology"},{"key":"117_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gut.50.2.241","volume":"50","author":"C Raetsch","year":"2002","unstructured":"Raetsch, C. et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 50, 241\u2013247 (2002).","journal-title":"Gut"},{"key":"117_CR41","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/aja.2010.117","volume":"13","author":"JF Smith","year":"2011","unstructured":"Smith, J. F. et al. Pentoxifylline treatment and penile calcifications in men with Peyronie\u2019s disease. Asian J.\u00a0Androl. 13, 322\u2013325 (2011).","journal-title":"Asian J. Androl."},{"key":"117_CR42","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","volume":"106","author":"MR Safarinejad","year":"2010","unstructured":"Safarinejad, M. R., Asgari, M. A., Hosseini, S. Y. & Dadkhah, F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2019s disease. BJU Int. 106, 240\u2013248 (2010).","journal-title":"BJU Int."},{"key":"117_CR43","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/j.1743-6109.2007.00614.x","volume":"4","author":"AJ Bella","year":"2007","unstructured":"Bella, A. J. et al. Peyronie\u2019s disease (CME). J. Sex. Med. 4, 1527\u20131538 (2007).","journal-title":"J. Sex. Med."},{"key":"117_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0022-5347(17)66108-1","volume":"81","author":"CJ Zarafonetis","year":"1959","unstructured":"Zarafonetis, C. J. & Horrax, T. M. Treatment of Peyronie\u2019s disease with potassium para-aminobenzoate (potaba). J. Urol. 81, 770\u2013772 (1959).","journal-title":"J. Urol."},{"key":"117_CR45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"W Weidner","year":"2005","unstructured":"Weidner, W., Hauck, E. W. & Schnitker, J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study. Eur. Urol. 47, 530\u2013535; discussion 535\u2013536 (2005).","journal-title":"Eur. Urol."},{"key":"117_CR46","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/S0022-5347(05)68868-4","volume":"161","author":"AI El-Sakka","year":"1999","unstructured":"El-Sakka, A. I. et al. The effects of colchicine on a Peyronie\u2019s-like condition in an animal model. J. Urol. 161, 1980\u20131983 (1999).","journal-title":"J. Urol."},{"issue":"Suppl. 3","key":"117_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sj.ijir.3900558","volume":"12","author":"MS Anderson","year":"2000","unstructured":"Anderson, M. S., Shankey, T. V., Lubrano, T. & Mulhall, J. P. Inhibition of Peyronie\u2019s plaque fibroblast proliferation by biologic agents. Int. J. Impot. Res. 12 (Suppl. 3), 25\u201331 (2000).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0090-4295(94)80155-X","volume":"44","author":"E Akkus","year":"1994","unstructured":"Akkus, E. et al. Is colchicine effective in Peyronie\u2019s disease? A pilot study. Urology 44, 291\u2013295 (1994).","journal-title":"Urology"},{"key":"117_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","volume":"12","author":"A Kadioglu","year":"2000","unstructured":"Kadioglu, A., Tefekli, A., Koksal, T., Usta, M. & Erol, H. Treatment of Peyronie\u2019s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int. J. Impot. Res. 12, 169\u2013175 (2000).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR50","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","volume":"91","author":"RM Prieto Castro","year":"2003","unstructured":"Prieto Castro, R. M. et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie\u2019s disease. BJU Int. 91, 522\u2013524 (2003).","journal-title":"BJU Int."},{"key":"117_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"MR Safarinejad","year":"2004","unstructured":"Safarinejad, M. R. Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study. Int. J. Impot. Res. 16, 238\u2013243 (2004).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/187152812798889321","volume":"11","author":"G Paulis","year":"2012","unstructured":"Paulis, G. & Brancato, T. Inflammatory mechanisms and oxidative stress in Peyronie\u2019s disease: therapeutic \u201crationale\u201d and related emerging treatment strategies. Inflamm. Allergy Drug Targets 11, 48\u201357 (2012).","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"117_CR53","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1002\/jcp.25049","volume":"230","author":"JM Carthy","year":"2015","unstructured":"Carthy, J. M. et al. Tamoxifen inhibits TGF-\u03b2-mediated activation of myofibroblasts by blocking non-Smad signaling through ERK1\/2. J. Cell. Physiol. 230, 3084\u20133092 (2015).","journal-title":"J. Cell. Physiol."},{"key":"117_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000357814","volume":"93","author":"AS Brandt","year":"2014","unstructured":"Brandt, A. S., Kamper, L., Kukuk, S., Haage, P. & Roth, S. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol. Int. 93, 320\u2013325 (2014).","journal-title":"Urol. Int."},{"key":"117_CR55","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","volume":"70","author":"DJ Ralph","year":"1992","unstructured":"Ralph, D. J., Brooks, M. D., Bottazzo, G. F. & Pryor, J. P. The treatment of Peyronie\u2019s disease with tamoxifen. Br.\u00a0J. Urol. 70, 648\u2013651 (1992).","journal-title":"Br. J. Urol."},{"key":"117_CR56","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"C Teloken","year":"1999","unstructured":"Teloken, C. et al. Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease. J. Urol. 162, 2003\u20132005 (1999).","journal-title":"J. Urol."},{"key":"117_CR57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pharmthera.2013.05.005","volume":"139","author":"G Yang","year":"2013","unstructured":"Yang, G., Nowsheen, S., Aziz, K. & Georgakilas, A. G. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol. Ther. 139, 392\u2013404 (2013).","journal-title":"Pharmacol. Ther."},{"key":"117_CR58","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1464-410X.2006.05969.x","volume":"97","author":"MD Bjekic","year":"2006","unstructured":"Bjekic, M. D., Vlajinac, H. D., Sipetic, S. B. & Marinkovic, J. M. Risk factors for Peyronie\u2019s disease: a case-control study. BJU Int. 97, 570\u2013574 (2006).","journal-title":"BJU Int."},{"key":"117_CR59","first-page":"142","volume":"5","author":"M Jalkut","year":"2003","unstructured":"Jalkut, M., Gonzalez-Cadavid, N. & Rajfer, J. Peyronie\u2019s fisease: a review. Rev. Urol. 5, 142\u2013148 (2003).","journal-title":"Rev. Urol."},{"key":"117_CR60","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/sj.ijir.3900912","volume":"14","author":"LA Levine","year":"2002","unstructured":"Levine, L. A. & Latchamsetty, K. C. Treatment of erectile dysfunction in patients with Peyronie\u2019s disease using sildenafil citrate. Int. J. Impot. Res. 14, 478\u2013482 (2002).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR61","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrurol.2010.24","volume":"7","author":"NF Gonzalez-Cadavid","year":"2010","unstructured":"Gonzalez-Cadavid, N. F. & Rajfer, J. Treatment of Peyronie\u2019s disease with PDE5 inhibitors: an antifibrotic strategy. Nat. Rev. Urol. 7, 215\u2013221 (2010).","journal-title":"Nat. Rev. Urol."},{"key":"117_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","volume":"97","author":"MG Ferrini","year":"2006","unstructured":"Ferrini, M. G., Kovanecz, I., Nolazco, G., Rajfer, J. & Gonzalez-Cadavid, N. F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie\u2019s disease. BJU Int. 97, 625\u2013633 (2006).","journal-title":"BJU Int."},{"key":"117_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/sj.ijir.3901596","volume":"20","author":"L Vignozzi","year":"2008","unstructured":"Vignozzi, L. et al. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int. J. Impot. Res. 20, 60\u201367 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000127335","volume":"80","author":"F Iacono","year":"2008","unstructured":"Iacono, F. et al. Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol. Int. 80, 249\u2013252 (2008).","journal-title":"Urol. Int."},{"key":"117_CR65","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/j.1743-6109.2011.02217.x","volume":"8","author":"E Chung","year":"2011","unstructured":"Chung, E., Deyoung, L. & Brock, G. B. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J.\u00a0Sex. Med. 8, 1472\u20131477 (2011).","journal-title":"J. Sex. Med."},{"key":"117_CR66","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","volume":"183","author":"U Ozturk","year":"2014","unstructured":"Ozturk, U. et al. Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction. Ir. J. Med. Sci. 183, 449\u2013453 (2014).","journal-title":"Ir. J. Med. Sci."},{"key":"117_CR67","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","volume":"35","author":"A Palmieri","year":"2012","unstructured":"Palmieri, A. et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and\u00a0erectile dysfunction: results from a prospective randomized trial. Int. J. Androl. 35, 190\u2013195 (2012).","journal-title":"Int. J. Androl."},{"key":"117_CR68","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1016\/S0022-5347(05)64173-0","volume":"168","author":"DJ Martin","year":"2002","unstructured":"Martin, D. J., Badwan, K., Parker, M. & Mulhall, J. P. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J. Urol. 168, 2483\u20132485 (2002).","journal-title":"J. Urol."},{"key":"117_CR69","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0022-4804(90)90197-A","volume":"49","author":"RC Lee","year":"1990","unstructured":"Lee, R. C. & Ping, J. A. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J. Surg. Res. 49, 463\u2013466 (1990).","journal-title":"J. Surg. Res."},{"key":"117_CR70","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1083\/jcb.98.5.1662","volume":"98","author":"J Aggeler","year":"1984","unstructured":"Aggeler, J., Frisch, S. M. & Werb, Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J. Cell Biol. 98, 1662\u20131671 (1984).","journal-title":"J. Cell Biol."},{"key":"117_CR71","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"WP Fitch 3rd","year":"2007","unstructured":"Fitch, W. P. 3rd, Easterling, W. J., Talbert, R. L., Bordovsky, M. J. & Mosier, M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie\u2019s disease \u2014 a placebo-controlled pilot study. J. Sex. Med. 4, 477\u2013484 (2007).","journal-title":"J. Sex. Med."},{"key":"117_CR72","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","volume":"12","author":"SM Stasi Di","year":"2011","unstructured":"Di Stasi, S. M. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12, 871\u2013879 (2011).","journal-title":"Lancet Oncol."},{"key":"117_CR73","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1097\/01.ju.0000056153.47716.d0","volume":"169","author":"LA Levine","year":"2003","unstructured":"Levine, L. A., Estrada, C. R., Shou, W. & Cole, A. Tunica albuginea tissue analysis after electromotive drug administration. J. Urol. 169, 1775\u20131778 (2003).","journal-title":"J. Urol."},{"key":"117_CR74","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1046\/j.1464-410X.2003.04242.x","volume":"91","author":"SM Stasi Di","year":"2003","unstructured":"Di Stasi, S. M. et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease. BJU Int. 91, 825\u2013829 (2003).","journal-title":"BJU Int."},{"key":"117_CR75","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"JM Greenfield","year":"2007","unstructured":"Greenfield, J. M., Shah, S. J. & Levine, L. A. Verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial. J. Urol. 177, 972\u2013975 (2007).","journal-title":"J. Urol."},{"key":"117_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","volume":"1","author":"AR Mehrsai","year":"2013","unstructured":"Mehrsai, A. R. et al. Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie\u2019s disease. Andrology 1, 129\u2013132 (2013).","journal-title":"Andrology"},{"key":"117_CR77","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom, W. J. et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease. J.\u00a0Urol. 176, 394\u2013398 (2006).","journal-title":"J. Urol."},{"key":"117_CR78","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0022-5347(17)67832-7","volume":"71","author":"GH Teasley","year":"1954","unstructured":"Teasley, G. H. Peyronie\u2019s disease: a new approach. J.\u00a0Urol. 71, 611\u2013614 (1954).","journal-title":"J. Urol."},{"key":"117_CR79","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/003655900455422","volume":"34","author":"A Lamprakopoulos","year":"2000","unstructured":"Lamprakopoulos, A., Zorzos, I. & Lykourinas, M. The\u00a0use of betamethasone and hyaluronidase injections in the treatment of Peyronie\u2019s disease. Scand. J. Urol. Nephrol. 34, 355\u2013360 (2000).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"117_CR80","first-page":"52","volume":"16","author":"A Demey","year":"2006","unstructured":"Demey, A., Chevallier, D., Bondil, P., Toubol, J. & Amiel, J. Is intracavernosal corticosteroid infiltration really useless in Peyronie\u2019s disease? [French]. Prog. Urol. 16, 52\u201357 (2006).","journal-title":"Prog. Urol."},{"key":"117_CR81","first-page":"165","volume":"70","author":"G Cipollone","year":"1998","unstructured":"Cipollone, G. et al. Betamethasone versus placebo in Peyronie\u2019s disease [Italian]. Arch. Ital. Urol. Androl. 70, 165\u2013168 (1998).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"117_CR82","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra, A. et al. Peyronie\u2019s disease: AUA guideline. J.\u00a0Urol. 194, 745\u2013753 (2015).","journal-title":"J. Urol."},{"key":"117_CR83","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","volume":"62","author":"K Hatzimouratidis","year":"2012","unstructured":"Hatzimouratidis, K. et al. EAU guidelines on penile curvature. Eur. Urol. 62, 543\u2013552 (2012).","journal-title":"Eur. Urol."},{"key":"117_CR84","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.juro.2012.08.191","volume":"189","author":"E Chung","year":"2013","unstructured":"Chung, E., Garcia, F., Young, L. D., Solomon, M. & Brock, G. B. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J. Urol. 189, 380\u2013384 (2013).","journal-title":"J. Urol."},{"key":"117_CR85","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","volume":"151","author":"LA Levine","year":"1994","unstructured":"Levine, L. A., Merrick, P. F. & Lee, R. C. Intralesional verapamil injection for the treatment of Peyronie\u2019s disease. J. Urol. 151, 1522\u20131524 (1994).","journal-title":"J. Urol."},{"key":"117_CR86","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/S0022-5347(01)64224-1","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine, L. A. Treatment of Peyronie\u2019s disease with intralesional verapamil injection. J. Urol. 158, 1395\u20131399 (1997).","journal-title":"J. Urol."},{"key":"117_CR87","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","volume":"168","author":"LA Levine","year":"2002","unstructured":"Levine, L. A., Goldman, K. E. & Greenfield, J. M. Experience with intraplaque injection of verapamil for Peyronie\u2019s disease. J. Urol. 168, 621\u2013625; discussion 625\u2013626 (2002).","journal-title":"J. Urol."},{"key":"117_CR88","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","volume":"51","author":"J Rehman","year":"1998","unstructured":"Rehman, J., Benet, A. & Melman, A. Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study. Urology 51, 620\u2013626 (1998).","journal-title":"Urology"},{"key":"117_CR89","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","volume":"69","author":"NE Bennett","year":"2007","unstructured":"Bennett, N. E., Guhring, P. & Mulhall, J. P. Intralesional verapamil prevents the progression of Peyronie\u2019s disease. Urology 69, 1181\u20131184 (2007).","journal-title":"Urology"},{"key":"117_CR90","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","volume":"41","author":"M Shirazi","year":"2009","unstructured":"Shirazi, M., Haghpanah, A. R., Badiee, M., Afrasiabi, M. A. & Haghpanah, S. Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study. Int. Urol. Nephrol. 41, 467\u2013471 (2009).","journal-title":"Int. Urol. Nephrol."},{"key":"117_CR91","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/j.1743-6109.2007.00674.x","volume":"5","author":"AW Shindel","year":"2008","unstructured":"Shindel, A. W., Bullock, T. L. & Brandes, S. Urologist practice patterns in the management of Peyronie\u2019s disease: a nationwide survey. J. Sex. Med. 5, 954\u2013964 (2008).","journal-title":"J. Sex. Med."},{"key":"117_CR92","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.urology.2007.01.080","volume":"69","author":"G Cavallini","year":"2007","unstructured":"Cavallini, G., Modenini, F. & Vitali, G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie\u2019s disease. Urology 69, 950\u2013954 (2007).","journal-title":"Urology"},{"key":"117_CR93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/00365599109024539","volume":"25","author":"MR Duncan","year":"1991","unstructured":"Duncan, M. R., Berman, B. & Nseyo, U. O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie\u2019s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand. J. Urol. Nephrol. 25, 89\u201394 (1991).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"117_CR94","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.prs.0000195073.73580.46","volume":"117","author":"A Al-Attar","year":"2006","unstructured":"Al-Attar, A. et al. Keloid pathogenesis and treatment. Plast. Reconstr. Surg. 117, 286\u2013300 (2006).","journal-title":"Plast. Reconstr. Surg."},{"key":"117_CR95","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.juro.2013.05.022","volume":"190","author":"LW Trost","year":"2013","unstructured":"Trost, L. W., Ates, E., Powers, M., Sikka, S. & Hellstrom, W. J. Outcomes of intralesional interferon-alpha2B for the treatment of Peyronie disease. J. Urol. 190, 2194\u20132199 (2013).","journal-title":"J. Urol."},{"key":"117_CR96","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2015.06.096","volume":"194","author":"CA Stewart","year":"2015","unstructured":"Stewart, C. A. et al. Intralesional injection of interferon-alpha2b improves penile curvature in men with Peyronie\u2019s disease independent of plaque location. J.\u00a0Urol. 194, 1704\u20131707 (2015).","journal-title":"J. Urol."},{"key":"117_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19900","volume":"19","author":"M Brazzelli","year":"2015","unstructured":"Brazzelli, M. et al. Collagenase clostridium histolyticum for the treatment of Dupuytren\u2019s contracture: systematic review and economic evaluation. Health Technol. Assess. 19, 1\u2013202 (2015).","journal-title":"Health Technol. Assess."},{"key":"117_CR98","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"GH Jordan","year":"2008","unstructured":"Jordan, G. H. The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a\u00a0prospective, single-center, non-placebo-controlled study. J. Sex. Med. 5, 180\u2013187 (2008).","journal-title":"J. Sex. Med."},{"key":"117_CR99","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard, M. et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J. Urol. 190, 199\u2013207 (2013).","journal-title":"J. Urol."},{"key":"117_CR100","unstructured":"US Food and Drug Administration. Drug safety information for Xiaflex. FDA \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM208737.pdf\n                    \n                   (2013)."},{"key":"117_CR101","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard, M. K., James, K., Riach, P. & Dorey, F. Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J. Urol. 149, 56\u201358 (1993).","journal-title":"J. Urol."},{"key":"117_CR102","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine, L. A. et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J. Sex. Med. 12, 248\u2013258 (2015).","journal-title":"J. Sex. Med."},{"key":"117_CR103","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz, L. I. et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two\u00a0large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 116, 650\u2013656 (2015).","journal-title":"BJU Int."},{"key":"117_CR104","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann, M. J. et al. Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie\u2019s disease. J. Urol. 195, 1051\u20131056 (2016).","journal-title":"J. Urol."},{"key":"117_CR105","doi-asserted-by":"crossref","unstructured":"Abdel Raheem, A., Capece, M. & Kalejaiye, O. Safety\u00a0and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease using a new modified shortened protocol. BJU Int. 120, 717\u2013723 (2017).","DOI":"10.1111\/bju.13932"},{"key":"117_CR106","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/S0022-5347(01)68184-9","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine, L. A. & Lenting, E. L. A surgical algorithm for the treatment of Peyronie\u2019s disease. J. Urol. 158, 2149\u20132152 (1997).","journal-title":"J. Urol."},{"key":"117_CR107","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jsm.12910","volume":"12","author":"D Papagiannopoulos","year":"2015","unstructured":"Papagiannopoulos, D., Yura, E. & Levine, L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie\u2019s disease: a single-institution retrospective review. J. Sex. Med. 12, 1474\u20131480 (2015).","journal-title":"J. Sex. Med."},{"key":"117_CR108","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","volume":"4","author":"BH Cordon","year":"2017","unstructured":"Cordon, B. H. et al. Superior cost effectiveness of penile plication versus intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities. Urol. Pract. 4, 118\u2013125 (2017).","journal-title":"Urol. Pract"},{"key":"117_CR109","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi, F. A., Anaissie, J., Zurawin, J., Sikka, S. C. & Hellstrom, W. J. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase Clostridium histolyticum for\u00a0Peyronie\u2019s disease. J. Sex. Med. 13, 684\u2013689 (2016).","journal-title":"J. Sex. Med."},{"key":"117_CR110","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0167-8140(99)00066-3","volume":"51","author":"KR Trott","year":"1999","unstructured":"Trott, K. R. & Kamprad, F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother. Oncol. 51, 197\u2013203 (1999).","journal-title":"Radiother. Oncol."},{"key":"117_CR111","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ijrobp.2014.12.025","volume":"91","author":"MW Nolan","year":"2015","unstructured":"Nolan, M. W. et al. Pudendal nerve and internal pudendal artery damage may contribute to radiation-induced erectile dysfunction. Int. J. Radiat. Oncol. Biol. Phys. 91, 796\u2013806 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"117_CR112","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/j.1743-6109.2012.02677.x","volume":"9","author":"JP Mulhall","year":"2012","unstructured":"Mulhall, J. P., Hall, M., Broderick, G. A. & Incrocci, L. Radiation therapy in Peyronie\u2019s disease. J. Sex. Med. 9, 1435\u20131441 (2012).","journal-title":"J. Sex. Med."},{"key":"117_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"A Palmieri","year":"2009","unstructured":"Palmieri, A. et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the\u00a0treatment of Peyronie\u2019s disease. Eur. Urol. 56, 363\u2013369 (2009).","journal-title":"Eur. Urol."},{"key":"117_CR114","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/01.ju.0000108060.30363.8d","volume":"171","author":"EW Hauck","year":"2004","unstructured":"Hauck, E. W. et al. Extracorporeal shock wave therapy for Peyronie\u2019s disease: exploratory meta-analysis of clinical trials. J. Urol. 171, 740\u2013745 (2004).","journal-title":"J. Urol."},{"key":"117_CR115","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","volume":"10","author":"G Hatzichristodoulou","year":"2013","unstructured":"Hatzichristodoulou, G. et al. Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J. Sex. Med. 10, 2815\u20132821 (2013).","journal-title":"J. Sex. Med."},{"key":"117_CR116","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/jsm.12082","volume":"10","author":"E Chung","year":"2013","unstructured":"Chung, E., De Young, L., Solomon, M. & Brock, G. B. Peyronie\u2019s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie\u2019s disease in a cell-culture strain system. J. Sex. Med. 10, 1259\u20131267 (2013).","journal-title":"J. Sex. Med."},{"key":"117_CR117","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1464-410X.2010.09365.x","volume":"106","author":"AA Raheem","year":"2010","unstructured":"Raheem, A. A. et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie\u2019s disease. BJU Int. 106, 1178\u20131180 (2010).","journal-title":"BJU Int."},{"key":"117_CR118","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jhsa.2012.04.023","volume":"37","author":"JM Agee","year":"2012","unstructured":"Agee, J. M. & Goss, B. C. The use of skeletal extension torque in reversing Dupuytren contractures of the proximal interphalangeal joint. J. Hand Surg. Am. 37, 1467\u20131474 (2012).","journal-title":"J. Hand Surg. Am."},{"key":"117_CR119","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/0266-7681(94)90220-8","volume":"19","author":"AJ Bailey","year":"1994","unstructured":"Bailey, A. J., Tarlton, J. F., Van der Stappen, J., Sims, T. J. & Messina, A. The continuous elongation technique for severe Dupuytren\u2019s disease. A biochemical mechanism. J. Hand Surg. Br. 19, 522\u2013527 (1994).","journal-title":"J. Hand Surg. Br."},{"key":"117_CR120","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","volume":"5","author":"LA Levine","year":"2008","unstructured":"Levine, L. A., Newell, M. & Taylor, F. L. Penile traction therapy for treatment of Peyronie\u2019s disease: a single-center pilot study. J. Sex. Med. 5, 1468\u20131473 (2008).","journal-title":"J. Sex. Med."},{"key":"117_CR121","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","volume":"6","author":"P Gontero","year":"2009","unstructured":"Gontero, P. et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie\u2019s disease. Results of a phase II prospective study. J. Sex. Med. 6, 558\u2013566 (2009).","journal-title":"J. Sex. Med."},{"key":"117_CR122","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jsm.12400","volume":"11","author":"JI Martinez-Salamanca","year":"2014","unstructured":"Martinez-Salamanca, J. I. et al. Acute phase Peyronie\u2019s disease management with traction device: a\u00a0nonrandomized prospective controlled trial with ultrasound correlation. J. Sex. Med. 11, 506\u2013515 (2014).","journal-title":"J. Sex. Med."},{"key":"117_CR123","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","volume":"14","author":"DJ Ralph","year":"2017","unstructured":"Ralph, D. J., Abdel Raheem, A. & Liu, G. Treatment of Peyronie\u2019s disease with collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J. Sex. Med. 14, 1430\u20131437 (2017).","journal-title":"J. Sex. Med."},{"key":"117_CR124","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1634\/stemcells.2007-0197","volume":"25","author":"G Chamberlain","year":"2007","unstructured":"Chamberlain, G., Fox, J., Ashton, B. & Middleton, J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25, 2739\u20132749 (2007).","journal-title":"Stem Cells"},{"key":"117_CR125","doi-asserted-by":"publisher","unstructured":"Milenkovic, U., Albersen, M. A. & Castiglione, F. The\u00a0mechanisms and potential of stem cell therapy for\u00a0penile fibrosis. Nat. Rev. Urol. \n                    https:\/\/doi.org\/10.1038\/s41585-018-0109-7\n                    \n                   (2018).","DOI":"10.1038\/s41585-018-0109-7"},{"key":"117_CR126","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.eururo.2012.09.034","volume":"63","author":"F Castiglione","year":"2013","unstructured":"Castiglione, F. et al. Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie\u2019s disease. Eur. Urol. 63, 551\u2013560 (2013).","journal-title":"Eur. Urol."},{"key":"117_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02395209\n                    \n                   (2015)."},{"key":"117_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02414308\n                    \n                   (2015)."},{"key":"117_CR129","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","volume":"28","author":"J Twidwell","year":"2016","unstructured":"Twidwell, J. & Levine, L. Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a\u00a0randomized, prospective, placebo-controlled pilot study. Int. J. Impot. Res. 28, 41\u201345 (2016).","journal-title":"Int. J. Impot. Res."},{"key":"117_CR130","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jsxm.2016.04.062","volume":"13","author":"E Chung","year":"2016","unstructured":"Chung, E. et al. Evidence-based management guidelines on Peyronie\u2019s disease. J. Sex. Med. 13, 905\u2013923 (2016).","journal-title":"J. Sex. Med."},{"key":"117_CR131","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","volume":"36","author":"N Dalbeth","year":"2014","unstructured":"Dalbeth, N., Lauterio, T. J. & Wolfe, H. R. Mechanism of action of colchicine in the treatment of gout. Clin.\u00a0Ther. 36, 1465\u20131479 (2014).","journal-title":"Clin. Ther."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0117-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-018-0117-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:24:33Z","timestamp":1684621473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-018-0117-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":131,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["117"],"URL":"https:\/\/doi.org\/10.1038\/s41585-018-0117-7","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"5 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A.L. declares that he has acted as a consultant for Coloplast Corporation, Boston Scientific, and Hybrid Medical and as a lecturer for Abbvie. P.T. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}